Company: AEMD
Filing Date: 2025-08-20
Form Type: S-1
Source: 0001683168-25-006352
Chunk: 36

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-20
Form: S-1
Chunk 36
---
 Company Offering

| · | The Company Offering is on a best-efforts basis with no minimum; we may raise less capital than needed.                                             |
| · | Investors may experience immediate and substantial dilution in the value of their shares upon purchase.                                             |
| · | Further dilution could occur from future option, warrant, or stock issuances.                                                                       |
| · | We have broad discretion in how we use offering proceeds, which may be used ineffectively.                                                          |
| · | Future sales or the perception of sales of our common stock could depress our stock price.                                                          |
| · | Warrant holders have no stockholder rights until exercise and may not realize value if our stock price stays low.                                   |
| · | No public market exists for the offered warrants or pre-funded warrants, limiting their liquidity and value.                                        |
| · | We will not receive meaningful funds upon the exercise of pre-funded warrants.                                                                      |
| · | Pre-funded warrants are subject to beneficial ownership limits, potentially preventing holders from exercising when it is financially advantageous. |

Reverse Stock Split

On June
6, 2025, the Company completed a reverse split of its outstanding shares of common stock at a ratio of 1-for-8. In connection with the
reverse stock split, every 8 shares of the Company’s issued and outstanding common stock was automatically converted into one share
of the Company’s common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole share. All
common stock amounts and prices in this Offering Circular reflect the consummation of the reverse split.

Our Corporate Information

On March
10, 1999, Aethlon, Inc., a California corporation, Hemex, Inc., a Delaware corporation and the accounting predecessor to Aethlon, Inc.,
and Bishop Equities, Inc., a publicly traded Nevada corporation, completed an Agreement and Plan of Reorganization structured to result
in Bishop Equities, Inc.’s acquisition of all of the outstanding common stock of Aethlon, Inc. and Hemex, Inc. Under the plan’s
terms, Bishop Equities, Inc. issued shares of its common stock to the stockholders of Aethlon, Inc. and Hemex, Inc. such that Bishop Equities,
Inc. then owned 100% of each company. Upon completion of the transaction, Bishop Equities, Inc. was renamed Aethlon Medical, Inc. Our
executive offices are located at 11555 Sorrento Valley Road, Suite